Full-Time

Associate Director

Learning Technology & Design

Confirmed live in the last 24 hours

CSL

CSL

10,001+ employees

Develops biotherapies and influenza vaccines

No salary listed

Senior, Expert

King of Prussia, PA, USA + 1 more

More locations: Boca Raton, FL, USA

This is a hybrid role, which offers a combination of an onsite and remote work schedule.

Category
Education
Required Skills
Data Analysis
Requirements
  • Bachelor’s degree in Instructional Design, Learning Technology, Learning & Development or a related field (Master’s degree preferred).
  • 8+ years of experience in learning design, instructional technology, learning analytics or a related field.
  • Workday Learning experience is required.
  • Proven track record of designing and implementing learning solutions using digital technologies.
  • Strong experience with learning management and learning experience systems (LMS/LXP), authoring tools, and analytics platforms.
  • Expertise in data analysis and measurement techniques for evaluating learning effectiveness.
  • Extensive program design/delivery experience across multiple topics, geographies/cultures, and learning modalities, including e-learning, instructor-led training, and virtual instructor-led training.
  • Project management experience, including managing timelines, budgets, and stakeholder communications.
  • Capable of influencing others and organizational outcomes without direct authority.
  • Strong knowledge of instructional design models such as ADDIE, SAM, and design thinking approaches.
  • Familiarity with e-learning standards (SCORM, xAPI, etc.).
  • Experience with data visualization tools to present learning insights.
  • Knowledge of adult learning principles and learner engagement strategies.
  • Excellent written, verbal, and interpersonal communication skills.
  • Proactive problem solver with a results-driven mindset.
  • Creative thinking and problem-solving skills, with a focus on driving innovation in learning solutions.
  • Ability to thrive in a fast-paced environment, balancing strategic priorities with operational demands.
Responsibilities
  • Lead the evaluation, selection, and implementation of learning technologies, including Learning Management/Experience Systems (LMS/LXP), content creation tools, and emerging digital learning platforms.
  • Drive innovation by integrating cutting-edge technology solutions (e.g., micro-learning, AI) to enhance learner engagement and accessibility.
  • Liaise with business units to strategize innovative learning tools and technology and provide best practices for leveraging Workday Learning.
  • Partner with Quality/Veeva and other LMS System owners to ensure enterprise alignment.
  • Lead change, training and communications for Workday Learning enhancements.
  • Responsible for measurement and reporting from Workday Learning.
  • Oversee the design and development of effective, scalable, and engaging learning experiences using instructional design best practices.
  • Apply learning theories and design frameworks to create multimodal learning solutions such as e-learning courses, virtual workshops, and performance support materials.
  • Manage instructional design vendor partnerships.
  • Develop and implement data-driven strategies to measure the effectiveness and ROI of learning initiatives, incorporating both quantitative and qualitative approaches.
  • Analyze learning data to assess engagement, knowledge retention, and performance improvement, providing actionable insights to stakeholders.
  • Drive measurement & analytics standardization and best practices across other business unit learning functions where possible.
  • Collaborate closely with and provide guidance to HR’s Employee Experience & Services Workday Learning support team.
  • Manage selection and deployment of instructional designers to HR and non-HR business projects as needed via third party vendor(s).
  • Collaborate with key stakeholders across departments to align learning initiatives with organizational goals.
  • Provide expertise to key stakeholders around the most effective training approaches to fit their learning objectives.
  • Lead complex learning projects from inception to completion, ensuring timely delivery and high-quality outcomes.
  • Build strong partnerships with internal business units and external vendors to deliver impactful learning solutions.
Desired Qualifications
  • Master’s degree preferred.

CSL develops and delivers biotherapies and influenza vaccines, focusing on rare and serious diseases. Their products include plasma-derived and recombinant therapies, which are created through extensive research and development. CSL serves healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. What sets CSL apart from competitors is its broad range of quality therapies and its commitment to saving lives, as well as its emphasis on diversity and inclusion within its workforce. The company's goal is to protect health and improve lives through its innovative treatments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL's gene therapy HEMGENIX shows sustained efficacy and safety over four years.
  • KOSTAIVE vaccine demonstrates superior immunogenicity and antibody persistence for up to 12 months.
  • CSL's performance-based reimbursement model for HEMGENIX sets new standards in Germany.

What critics are saying

  • Emerging competition in gene therapy could impact CSL's market share.
  • High costs of gene therapies like HEMGENIX may face pushback from healthcare systems.
  • Reliance on plasma-derived therapies exposes CSL to plasma supply shortages.

What makes CSL unique

  • CSL offers the first gene therapy for hemophilia B, HEMGENIX.
  • CSL's KOSTAIVE is the first self-amplifying mRNA COVID-19 vaccine approved in Europe.
  • CSL's diverse portfolio includes plasma-derived therapies, recombinant therapies, and influenza vaccines.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Company News

PharmiWeb
Apr 14th, 2025
First Patient Treated With Hemgenix® (Etranacogene Dezaparvovec) Gene Therapy For Haemophilia B In Austria

Vienna, Austria – 9 April 2025 - CSL Behring Austria today announced that the first haemophilia B patient in Austria was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Comprehensive Care Center of the University Hospital of Medicine Vienna.HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1“It is a great opportunity for people with hemophilia B to live a symptom-free life for many years,” explains hematologist Univ.-Prof. Priv.-Doz. Dr Cihan Ay from the Medical University of Vienna, University Clinic for Internal Medicine I Clinical Department for Hematology and Hemostaseology."For the community of affected patients and their families, this represents an enormously significant milestone: the ability to treat hemophilia with gene therapy, and the fact that this option is now available in Austria, is something our community has been eagerly anticipating and hoping for over decades," says Thomas Schindl, MA, Chairman of the Austrian Hemophilia Society (ÖHG)."We are proud and grateful to offer haemophilia B patients in Austria a treatment option that has the potential to transform their lives," said Dr Beate Natmessnig, Managing Director of CSL Behring Austria. "This achievement is the result of outstanding regional and national collaboration among all parties involved and is a strong testament to Austria's innovative capabilities."HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022

PharmiWeb
Apr 3rd, 2025
Csl Behring And Gkv-Spitzenverband Agree On Reimbursement Price For Hemgenix® – Europe'S First Gene Therapy For Haemophilia B

Marburg, Germany, 2 April 2025 – CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX®. This agreement marks the availability of the first gene therapy approved in Europe for haemophilia B under an innovative, national, success-based reimbursement model, being implemented for the first time in Germany.HEMGENIX® represents significant progress in the treatment of haemophilia B. The aim of this one-time gene therapy is to eliminate the need for regular factor IX infusions, thereby offering patients the possibility of more freedom from prophylaxis and significantly improving their quality of life.1-4 This development not only provides substantial relief for those affected but also has the potential to reduce long-term costs for the healthcare system.‘The performance-based payment model at national level which was agreed with the GKV-Spitzenverband is unique in Germany. It addresses key reimbursement challenges, such as the question of long-term efficacy, which is inherent for any one-time therapy. Reimbursement is linked to treatment success of the individual patient,’ explains Stefan Neudoerfer, CSL Behring's chief negotiator in Germany.Moreover, this reimbursement model reflects the high therapeutic and innovative value of HEMGENIX® and sets new standards for integrating innovative gene therapies into the German healthcare system.‘The agreement on the reimbursement price of HEMGENIX® is a decisive step for the care of people with haemophilia B in Germany. It enables access to a groundbreaking therapy and recognises the long-term medical and economic benefits of gene therapy,’ explains Christian Wieszner, Managing Director of CSL Behring Germany.With this agreement, CSL Behring is underlining its commitment to innovative therapies that sustainably improve the lives of patients

PR Newswire
Feb 14th, 2025
European Commission Approves Csl And Arcturus Therapeutics' Kostaive®, The First Self-Amplifying Mrna Covid-19 Vaccine

- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA COVID-19 vaccines in clinical trialsWALTHAM, Mass. and SAN DIEGO, Feb. 14, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE ® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission (EC). KOSTAIVE is currently marketed in Japan against COVID-19

PR Newswire
Feb 7th, 2025
Csl Behring'S Gene Therapy Hemgenix® (Etranacogene Dezaparvovec-Drlb) Four Years Post-Infusion Data Continue To Show Sustained Efficacy And Safety In Adults With Hemophilia B

94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatmentMean factor IX activity levels were sustained at near normal levels of 37% through four years post-treatment, reinforcing the efficacy of HEMGENIX in the treatment of hemophilia BPhase 3 HOPE-B data showed that a one-time treatment with HEMGENIX provided long-term bleed protection as mean adjusted annualized bleeding rate (ABR) for all bleeds was reduced by approximately 90% from lead-in as compared to year fourKING OF PRUSSIA, Pa., Feb. 7, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of HEMGENIX® (etranacogene dezaparvovec-drlb) for adults living with hemophilia B. In an oral presentation at the 18th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), data showed that through four years, HEMGENIX continues to deliver elevated and sustained factor IX activity levels, can offer long-term and greater bleed protection compared to prophylactic treatment, can eliminate the need for routine factor IX prophylaxis, and maintains a favorable safety profile. Approved in 2022 by the U.S. Food and Drug Administration (FDA), HEMGENIX is the first gene therapy for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening bleeding, or have repeated, serious spontaneous bleeding episodes. It is also the only approved gene therapy for hemophilia B that can treat adult patients with and without AAV5 neutralizing antibodies thereby providing the potential for a greater number of eligible patients to be treated."Hemophilia B can cause spontaneous bleeds into the joints, resulting in extreme pain and progressive, arthritis-like damage, which can lead to permanent physical debility," said Steven Pipe, MD, Professor of Pediatrics and Pathology, Laurence A

PharmiWeb
Jan 21st, 2025
First Patients Treated With Hemgenix® (Etranacogene Dezaparvovec) Gene Therapy For Haemophilia B In Denmark

First patients treated with HEMGENIX® (etranacogene dezaparvovec) gene therapy for haemophilia B in Denmark. COPENHAGEN, DENMARK—21 January 2025 — CSL Behring Denmark today announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec). HEMGENIX® is the first one-time gene therapy to be approved in Europe for the treatment of adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1